ATARA BIOTHERAPEUTICS, INC. Comprehensive Income
ATARA BIOTHERAPEUTICS, INC. (ATRA) reported Comprehensive Income of -$4.84 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-12
- ATARA BIOTHERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$4.84M, a 302.60% decline year-over-year.
- ATARA BIOTHERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$4.15M, a 110.91% decline year-over-year.
- ATARA BIOTHERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$3.41M.
- ATARA BIOTHERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$4.30M.
- ATARA BIOTHERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was $32.68M.
- ATARA BIOTHERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$85.19M.
- ATARA BIOTHERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$274.26M.
- ATARA BIOTHERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$230.00M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$4.84M 10-Q · filed 2026-08-12 | -$8.98M 10-Q · filed 2026-08-12 | -$12.39M derived: sum of 3 quarters · filed 2026-08-12 | -$16.69M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$4.15M 10-Q · filed 2026-05-12 | -$7.55M derived: sum of 2 quarters · filed 2026-05-12 | -$11.85M derived: sum of 3 quarters · filed 2026-05-12 | -$9.47M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$3.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$7.71M derived: sum of 2 quarters · filed 2026-03-16 | -$5.32M derived: sum of 3 quarters · filed 2026-08-12 | $32.68M 10-K · filed 2026-03-16 |
| 2025-09-30 | -$4.30M 10-Q · filed 2025-11-12 | -$1.91M derived: sum of 2 quarters · filed 2026-08-12 | $36.09M 10-Q · filed 2025-11-12 | $23.38M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $2.39M 10-Q · filed 2026-08-12 | $40.39M 10-Q · filed 2026-08-12 | $27.68M derived: sum of 3 quarters · filed 2026-08-12 | $5.81M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $38.00M 10-Q · filed 2026-05-12 | $25.30M derived: sum of 2 quarters · filed 2026-05-12 | $3.42M derived: sum of 3 quarters · filed 2026-05-12 | -$15.59M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$12.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$34.58M derived: sum of 2 quarters · filed 2026-03-16 | -$53.59M derived: sum of 3 quarters · filed 2026-03-16 | -$85.19M 10-K · filed 2026-03-16 |
| 2024-09-30 | -$21.87M 10-Q · filed 2025-11-12 | -$40.88M derived: sum of 2 quarters · filed 2025-11-12 | -$72.48M 10-Q · filed 2025-11-12 | -$132.57M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$19.01M 10-Q · filed 2025-08-11 | -$50.61M 10-Q · filed 2025-08-11 | -$110.69M derived: sum of 3 quarters · filed 2025-08-11 | -$180.13M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | -$31.60M 10-Q · filed 2025-05-15 | -$91.69M derived: sum of 2 quarters · filed 2025-05-15 | -$161.12M derived: sum of 3 quarters · filed 2025-05-15 | -$231.93M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | -$60.08M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | -$129.52M derived: sum of 2 quarters · filed 2025-03-07 | -$200.32M derived: sum of 3 quarters · filed 2025-03-07 | -$274.26M 10-K · filed 2025-03-07 |
| 2023-09-30 | -$69.44M 10-Q · filed 2024-11-12 | -$140.24M derived: sum of 2 quarters · filed 2024-11-12 | -$214.18M 10-Q · filed 2024-11-12 | -$287.86M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$70.80M 10-Q · filed 2024-08-12 | -$144.75M 10-Q · filed 2024-08-12 | -$218.43M derived: sum of 3 quarters · filed 2024-08-12 | -$302.86M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | -$73.94M 10-Q · filed 2024-05-09 | -$147.62M derived: sum of 2 quarters · filed 2024-05-09 | -$232.05M derived: sum of 3 quarters · filed 2024-05-09 | -$214.31M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$73.68M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$158.11M derived: sum of 2 quarters · filed 2024-03-28 | -$140.37M derived: sum of 3 quarters · filed 2024-03-28 | -$230.00M 10-K · filed 2024-03-28 |
| 2022-09-30 | -$84.43M 10-Q · filed 2023-11-01 | -$66.69M derived: sum of 2 quarters · filed 2023-11-01 | -$156.32M 10-Q · filed 2023-11-01 | -$250.06M derived: sum of 4 quarters · filed 2023-11-01 |
| 2022-06-30 | $17.74M 10-Q · filed 2023-08-08 | -$71.89M 10-Q · filed 2023-08-08 | -$165.63M derived: sum of 3 quarters · filed 2023-08-08 | -$250.33M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$89.63M 10-Q · filed 2023-05-08 | -$183.37M derived: sum of 2 quarters · filed 2023-05-08 | -$268.07M derived: sum of 3 quarters · filed 2023-05-08 | -$351.96M derived: sum of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | -$93.74M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-08 | -$178.44M derived: sum of 2 quarters · filed 2023-02-08 | -$262.33M derived: sum of 3 quarters · filed 2023-02-08 | -$340.81M 10-K · filed 2023-02-08 |
| 2021-09-30 | -$84.70M 10-Q · filed 2022-11-08 | -$168.59M derived: sum of 2 quarters · filed 2022-11-08 | -$247.06M 10-Q · filed 2022-11-08 | -$328.60M derived: sum of 4 quarters · filed 2023-02-08 |
| 2021-06-30 | -$83.89M 10-Q · filed 2022-08-08 | -$162.36M 10-Q · filed 2022-08-08 | -$243.90M derived: sum of 3 quarters · filed 2023-02-08 | -$318.53M derived: sum of 4 quarters · filed 2023-02-08 |
| 2021-03-31 | -$78.47M 10-Q · filed 2022-05-05 | -$160.01M derived: sum of 2 quarters · filed 2023-02-08 | -$234.64M derived: sum of 3 quarters · filed 2023-02-08 | -$311.49M derived: sum of 4 quarters · filed 2023-02-08 |
| 2020-12-31 | -$81.54M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-08 | -$156.17M derived: sum of 2 quarters · filed 2023-02-08 | -$233.02M derived: sum of 3 quarters · filed 2023-02-08 | -$306.54M 10-K · filed 2023-02-08 |
| 2020-09-30 | -$74.63M 10-Q · filed 2021-11-04 | -$151.48M derived: sum of 2 quarters · filed 2021-11-04 | -$225.01M 10-Q · filed 2021-11-04 | -$303.51M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | -$76.85M 10-Q · filed 2021-08-09 | -$150.38M 10-Q · filed 2021-08-09 | -$228.88M derived: sum of 3 quarters · filed 2022-02-28 | -$300.72M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | -$73.53M 10-Q · filed 2021-05-04 | -$152.03M derived: sum of 2 quarters · filed 2022-02-28 | -$223.87M derived: sum of 3 quarters · filed 2022-02-28 | -$298.06M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | -$78.51M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$150.34M derived: sum of 2 quarters · filed 2022-02-28 | -$224.54M derived: sum of 3 quarters · filed 2022-02-28 | -$290.42M 10-K · filed 2022-02-28 |
| 2019-09-30 | -$71.83M 10-Q · filed 2020-11-09 | -$146.03M derived: sum of 2 quarters · filed 2020-11-09 | -$211.91M 10-Q · filed 2020-11-09 | -$291.81M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | -$74.19M 10-Q · filed 2020-08-05 | -$140.07M 10-Q · filed 2020-08-05 | -$219.97M derived: sum of 3 quarters · filed 2021-03-01 | -$278.28M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | -$65.88M 10-Q · filed 2020-05-06 | -$145.78M derived: sum of 2 quarters · filed 2021-03-01 | -$204.09M derived: sum of 3 quarters · filed 2021-03-01 | -$254.95M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | -$79.90M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | -$138.21M derived: sum of 2 quarters · filed 2021-03-01 | -$189.07M derived: sum of 3 quarters · filed 2021-03-01 | -$230.89M 10-K · filed 2021-03-01 |
| 2018-09-30 | -$58.30M 10-Q · filed 2019-11-07 | -$109.17M derived: sum of 2 quarters · filed 2019-11-07 | -$150.99M 10-Q · filed 2019-11-07 | -$186.36M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | -$50.86M 10-Q · filed 2019-08-08 | -$92.68M 10-Q · filed 2019-08-08 | -$128.06M derived: sum of 3 quarters · filed 2020-02-27 | -$159.13M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | -$41.82M 10-Q · filed 2019-05-09 | -$77.19M derived: sum of 2 quarters · filed 2020-02-27 | -$108.26M derived: sum of 3 quarters · filed 2020-02-27 | -$135.65M derived: sum of 4 quarters · filed 2020-02-27 |
| 2017-12-31 | -$35.38M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | -$66.45M derived: sum of 2 quarters · filed 2020-02-27 | -$93.84M derived: sum of 3 quarters · filed 2020-02-27 | -$119.46M 10-K · filed 2020-02-27 |
| 2017-09-30 | -$31.07M 10-Q · filed 2018-11-06 | -$58.46M derived: sum of 2 quarters · filed 2018-11-06 | -$84.08M 10-Q · filed 2018-11-06 | -$102.54M derived: sum of 4 quarters · filed 2019-02-26 |
| 2017-06-30 | -$27.39M 10-Q · filed 2018-08-01 | -$53.01M 10-Q · filed 2018-08-01 | -$71.47M derived: sum of 3 quarters · filed 2019-02-26 | -$97.00M derived: sum of 4 quarters · filed 2019-02-26 |
| 2017-03-31 | -$25.62M 10-Q · filed 2018-05-08 | -$44.08M derived: sum of 2 quarters · filed 2019-02-26 | -$69.61M derived: sum of 3 quarters · filed 2019-02-26 | -$88.34M derived: sum of 4 quarters · filed 2019-02-26 |
| 2016-12-31 | -$18.45M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | -$43.98M derived: sum of 2 quarters · filed 2019-02-26 | -$62.72M derived: sum of 3 quarters · filed 2019-02-26 | -$78.71M 10-K · filed 2019-02-26 |
| 2016-09-30 | -$25.53M 10-Q · filed 2017-11-09 | -$44.27M derived: sum of 2 quarters · filed 2017-11-09 | -$60.26M 10-Q · filed 2017-11-09 | -$82.08M derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-06-30 | -$18.74M 10-Q · filed 2017-08-07 | -$34.73M 10-Q · filed 2017-08-07 | -$56.55M derived: sum of 3 quarters · filed 2018-02-27 | -$68.30M derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-03-31 | -$15.99M 10-Q · filed 2017-05-04 | -$37.81M derived: sum of 2 quarters · filed 2018-02-27 | -$49.56M derived: sum of 3 quarters · filed 2018-02-27 | -$64.55M derived: sum of 4 quarters · filed 2018-02-27 |
| 2015-12-31 | -$21.82M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | -$33.57M derived: sum of 2 quarters · filed 2018-02-27 | -$48.56M derived: sum of 3 quarters · filed 2018-02-27 | -$57.64M 10-K · filed 2018-02-27 |
| 2015-09-30 | -$11.75M 10-Q · filed 2016-11-04 | -$26.74M derived: sum of 2 quarters · filed 2016-11-04 | -$35.82M 10-Q · filed 2016-11-04 | -$46.44M derived: sum of 4 quarters · filed 2017-03-09 |
| 2015-06-30 | -$14.99M 10-Q · filed 2016-08-08 | -$24.07M 10-Q · filed 2016-08-08 | -$34.69M derived: sum of 3 quarters · filed 2017-03-09 | -$40.62M derived: sum of 4 quarters · filed 2017-03-09 |
| 2015-03-31 | -$9.08M 10-Q · filed 2016-05-06 | -$19.69M derived: sum of 2 quarters · filed 2017-03-09 | -$25.62M derived: sum of 3 quarters · filed 2017-03-09 | -$30.12M derived: sum of 4 quarters · filed 2017-03-09 |
| 2014-12-31 | -$10.62M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-09 | -$16.55M derived: sum of 2 quarters · filed 2017-03-09 | -$21.05M derived: sum of 3 quarters · filed 2017-03-09 | -$28.11M 10-K · filed 2017-03-09 |
| 2014-09-30 | -$5.93M 10-Q · filed 2015-11-06 | -$10.43M derived: sum of 2 quarters · filed 2015-11-06 | -$17.49M 10-Q · filed 2015-11-06 | |
| 2014-06-30 | -$4.50M 10-Q · filed 2015-08-07 | -$11.56M 10-Q · filed 2015-08-07 | ||
| 2013-12-31 | -$8.77M 10-K · filed 2016-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |